Leif W. Ellisen
Runs breast medical oncology at MGH and studies the tumour-suppressor biology behind hereditary and triple-negative breast cancer.
Physician-scientist whose laboratory works on p63/p73 and DNA damage response in breast and squamous cancers, alongside leading MGH's breast oncology programme.
| Title | Journal | Year |
|---|---|---|
| ΔNp63α represses anti-proliferative genes via H2A.Z deposition | Genes & Development | 2012 |
Pages like this
not linked directly; found by shared links- TechnologyMirai (MIT breast cancer risk from mammograms)
Shares Massachusetts General Hospital Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonLori J. Pierce
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonSabine Linn
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonJennifer K. Litton
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CollectionSusan G. Komen
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TermMastectomy
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.